A Tale of Two (and Three) Dimensions: Analysis pipeline for clinical an small animal pathology with applications in pancreatic tumor hypoxia, radiation-induced fibrosis, and prostate gland segmentation*
Trevor McKee, PhD , STTARR Image Analysis Manager, Princess Margaret Cancer Center
The STTARR Innovation Centre, located in Toronto at the Princess Margaret Cancer Centre, is a small animal imaging facility with capabilities for PET, SPECT, CT, MRI and optical imaging integrated with a correlative histopathology lab. STTARR provides image analysis services for its users, and the wider research community, having processed...
Tissue Phenomics: The Discovery of Prognostic and Predictive Histological Phenotypes
Gerd Binnig, PhD, Founder & CTO, Definiens AG
Histological phenotypes generally play an essential role in diagnostics, but in particular in oncology there is a growing need for selecting the right patients for the right treatments. Oncology is a rapidly evolving field with many new treatment methods being discovered. To finally cope with the complexity of cancer, the...
Information-rich Pan-omics in Situ*
George Church, PhD, Professor of Genetics, Harvard Medical School
To get the most out of tissues, we need to be able to optimize imaging resolution and targeted molecular identification. Three new technologies are being combined with each other and new analytic tools -- Fluorescent in situ Sequencing (FISSEQ), Oligo-Paints and Expansion Microscopy. These enable identification of many subsets of...
Quantitative Image Analysis to Study MM-302 Cardiac and Tumor Distribution, and HER2-mediated Delivery*
Elena Geretti, PhD, Principal Scientist, Merrimack Pharmaceuticals
MM-302 is an antibody-liposomal drug conjugate designed specifically to target doxorubicin to HER2-overexpressing tumor cells and limit delivery to non-target cells. Quantitative image analysis was applied to gain insights into the preclinical cardiac and tumor delivery and distribution of MM-302. Confocal fluorescence microscopy images of mouse cardiac tissue were analyzed with...
Quantitative Immunohistochemistry for Development of Predictive Biomarkers in Oncology Clinical Trials
Belma Dogdas, PhD, Associate Principle Scientist, Merck
In oncology studies, biomarkers have been effectively used to measure tumor progression and to evaluate efficacy of therapies. Increasingly they have been utilized to stratify different patient groups and to develop personalized therapeutic strategies. Towards this goal, immunohistochemistry (IHC) has been playing an increasing role to help understand the mechanism...